Earnings Insights · Altria (MO) · Q3 FY2026
Altria (MO) Q3 FY2026: Altria Q3 2026 Earnings: Raised EPS Outlook Offsets Pressure in Oral Tobacco
By AlgovestIQ ResearchPublished
Read Altria Group’s results announcement (Form 8-K, filed Oct 29, 2026)
Key earnings findings
Altria (MO) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Altria reported Q3 FY2026 revenue of $5.44B against the $5.31B analyst estimate, a 2.4% beat, and EPS of $1.52 against the $1.51 analyst estimate, a 0.7% beat.
- MO closed at $76.75 on Oct 29, 2026, up 5.2% from $72.99 on Oct 28, 2026, the last close before the results were released.
- Altria Group reported third-quarter net revenue of $6.1B, up 1.0% from a year earlier, while reported diluted EPS increased 7.1% to $1.51.
Sources: Altria Group results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Altria beat earnings expectations?
- Revenue surprise across the last 8 reported quarters has ranged from -2.1% to 17.0%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Altria Group reported third-quarter net revenue of $6.1B, up 1.0% from a year earlier, while reported diluted EPS increased 7.1% to $1.51. Adjusted diluted EPS rose 4.8% to $1.52, supported by pricing in smokeable products, higher earnings from Anheuser-Busch InBev, and a lower share count.
The quarter reinforced the resilience of Altria’s cigarette profit engine, even as consumers continued to trade toward discount products. But the smoke-free transition remains uneven: on! pouch shipments grew, yet market share within nicotine pouches declined and the oral tobacco segment’s profit fell as moist smokeless tobacco volumes weakened and investment increased.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Net revenue | $6.132B | Up 1.0% |
| Revenue net of excise taxes | $5.441B | Up 3.6% |
| Reported diluted EPS | $1.51 | Up 7.1% |
| Adjusted diluted EPS | $1.52 | Up 4.8% |
| Operating companies income | $3.399B | Up 2.2% |
| Smokeable products revenue | $5.432B | Up 0.8% |
| Smokeable products adjusted OCI | $3.072B | Up 3.9% |
| Smokeable products adjusted OCI margin | 64.5% | Up 0.1 percentage point |
| Oral tobacco products revenue | $688M | Down 0.1% |
| Oral tobacco products adjusted OCI | $443M | Down 3.7% |
| Oral tobacco products adjusted OCI margin | 66.4% | Down 2.8 percentage points |
| Adjusted equity earnings from ABI | $191M | Up 21.7% |
| Share repurchases | $400M | 5.9M shares repurchased |
OCI refers to operating companies income, Altria’s segment profit measure before general corporate expenses and amortization of intangibles.
The Bigger Story
Altria’s investment case continues to rest on whether its combustible tobacco business can fund shareholder returns and smoke-free investment faster than its legacy volumes erode. In the third quarter, that equation remained favorable financially: cigarette pricing, modest margin expansion, ABI earnings and repurchases produced mid-single-digit adjusted EPS growth.
The strategic complication is that consumer downtrading is increasingly visible. Marlboro retained its premium-category leadership, but its total cigarette-category share declined as discount brands gained ground. Altria has partly countered that shift with Basic, whose retail share rose sharply, and with Marlboro Cowboy Cut, a lower-priced premium offering intended to retain price-sensitive Marlboro smokers.
Meanwhile, nicotine pouches continue to expand as a category, but Altria’s on! is competing from a weaker share position. Shipment growth was healthy, particularly around new product launches, but on!’s share of the nicotine pouch category fell 1.3 percentage points year over year to 13.5%. The central question is whether new strengths, flavors and retail placement can reverse that trend without creating a lasting drag on oral tobacco margins.
Revenue and Operating Performance
Third-quarter net revenue rose 1.0% to $6.132B, while revenue net of excise taxes increased 3.6% to $5.441B. The difference reflects lower excise taxes, particularly in the smokeable segment, rather than underlying sales growth alone.
Smokeable products remained the main contributor. Segment revenue increased 0.8% to $5.432B, and revenue net of excise taxes grew 3.7% to $4.762B. Higher pricing and refunds of taxes and duties paid on imported cigarettes more than offset lower shipment volumes, higher promotional spending and a mix shift toward discount brands.
Reported domestic cigarette shipment volume declined 2.9%. Adjusted for trade inventory movements, Altria estimated that its cigarette volume fell about 4%, compared with an estimated 5% decline for the total domestic industry. That relative performance reflects retail share gains for Altria’s overall cigarette portfolio, although it does not eliminate the longer-term pressure from declining cigarette consumption.
Marlboro shipments fell 6.4% year over year, while discount-brand shipments rose 40.5%. The mix shift was substantial, with discount volume increasing to 1.704 billion sticks from 1.213 billion a year earlier. Basic’s retail share rose 1.4 percentage points to 4.1%, while total Altria cigarette retail share increased 0.3 percentage points to 45.7%.
Marlboro’s overall cigarette retail share fell 1.0 percentage point to 39.5%, but its premium-segment share increased 0.3 point to 60.0%. Management attributed part of that premium performance to Cowboy Cut, which has been distributed to roughly 100,000 stores representing about 75% of cigarette volume. The product is positioned as a premium Marlboro option for more price-sensitive customers, rather than a full shift of the franchise into discount pricing.
The oral tobacco segment was weaker. Revenue was effectively flat at $688M, as pricing offset lower shipment volume and higher promotional investment. Segment shipment volume declined 4.3%, with on! growth unable to offset declines in Copenhagen and Skoal.
Copenhagen shipment volume declined 10.1% and Skoal volume fell 12.6%. On! shipments increased 13.3% to 47.8 million cans, though management said some pipeline inventory accompanied the national rollout of 12-milligram products and new flavor extensions. That makes the shipment growth stronger than the segment trend, but not necessarily a clean indication of end-market consumption in the quarter.
Profitability and Margins
Reported operating companies income rose 2.2% to $3.399B. Reported diluted EPS grew faster, at 7.1%, helped by higher income from Altria’s ABI investment and fewer diluted shares outstanding.
Adjusted diluted EPS rose 4.8% to $1.52 from $1.45. Adjusted net earnings increased 4.2% to $2.547B. Altria repurchased shares during the year, reducing weighted-average diluted shares outstanding by 0.7% to 1.669 billion.
Smokeable products generated the bulk of earnings growth. Adjusted OCI increased 3.9% to $3.072B, and adjusted OCI margin edged up 0.1 percentage point to 64.5%. Pricing and higher tax-and-duty refunds more than covered volume declines, greater promotional spending, unfavorable mix and higher manufacturing costs.
The margin result is notable because the growing discount mix could otherwise pressure profitability. Management said price realization was 4.4% in the quarter, aided by product mix within both the Marlboro and Basic portfolios. Still, sustaining profit growth will require pricing and cost management to continue outpacing volume declines and trade-down pressure.
Oral tobacco profitability moved in the opposite direction. Adjusted OCI declined 3.7% to $443M, while adjusted OCI margin fell 2.8 percentage points to 66.4%. Lower segment volume, higher costs and promotional investment outweighed pricing. The reported result also included costs related to the planned consolidation of U.S. Smokeless Tobacco manufacturing operations.
Reported EPS included several special items. Third-quarter reported results reflected $0.01 per share each from tobacco and health litigation-related costs and intangible amortization, partly offset by a $0.02 per share ABI-related benefit. These items left adjusted EPS only $0.01 above reported EPS in the quarter.
Demand, Customers and Pricing
Consumer affordability remains a material operating issue. Management said inflation and higher gasoline prices continued to pressure household budgets, helping drive the discount cigarette category’s retail share up 2.0 percentage points to 34.1%.
Altria’s portfolio strategy is designed to preserve customers across price points. Marlboro Cowboy Cut is intended to protect the premium franchise, while Basic gives the company a competitive discount option. The approach helped total Altria cigarette share rise, but the underlying market shift still matters because discount products generally carry lower revenue per unit and may require greater promotional support.
Nicotine pouches remain the main growth area within oral tobacco. Altria estimated total oral tobacco industry volume increased 5.5% over the six months ended September 30, driven by pouches, while traditional moist smokeless tobacco contracted. Nicotine pouches represented 61.2% of the oral category in the third quarter, up 5.8 percentage points from a year earlier.
On! held 8.3% of the total oral category, up 0.1 percentage point year over year but down 0.3 point sequentially. More importantly, on!’s nicotine pouch share fell to 13.5% from 14.8% a year earlier and from 14.4% in the prior quarter. Altria is responding with broader distribution of on! PLUS 12-milligram products and flavor additions, including Blueberry Mint, Mango Pineapple and a planned Watermelon Mint launch in select stores during the fourth quarter.
Management also linked the moderation in cigarette-industry declines partly to lower consumption of illicit e-vapor products and greater enforcement activity. It estimated the number of adult vapers declined by roughly 1 million year over year to approximately 20 million at the end of September, primarily because fewer consumers used illicit products. That remains management’s assessment rather than a reported industry measure.
What is Altria’s guidance for full-year 2026?
Altria raised its 2026 adjusted diluted EPS guidance to a range of $5.66 to $5.74, representing growth of 4.5% to 6.0% from adjusted diluted EPS of $5.42 in 2025.
Management said the outlook assumes continued moderated e-vapor industry growth, heightened macroeconomic uncertainty for adult nicotine consumers, investment in contract manufacturing capabilities, reinvestment of savings from its Optimize & Accelerate initiative, and continued investment behind its broader strategy.
The outlook also assumes NJOY ACE does not return to the market in 2026. Management said it has addressed the patent issues that removed the product from the market and plans to re-enter e-vapor eventually, but did not provide a launch date. It emphasized that any return would be approached with an objective of achieving profitability over time.
Balance Sheet, Cash Flow and Capital
Altria continued to prioritize shareholder distributions. It paid $1.7B in dividends during the third quarter and $5.3B through the first nine months. The quarterly dividend was increased 4.7% in August to $1.11 per share, or $4.44 on an annualized basis.
The company repurchased $400M of stock in the third quarter, buying 5.9 million shares at an average price of $68.52. Through nine months, repurchases totaled $735M. The board also authorized a $1B expansion of the repurchase program, which now runs through December 31, 2027.
At September 30, cash and cash equivalents were $2.697B, down from $4.474B at year-end. Total debt declined to $24.061B from $25.709B. Management said debt to EBITDA was 1.9x, consistent with its approximate 2x target.
Contract-manufactured export cigarette volume rose sharply to 1.595 billion sticks from 311 million in the prior-year quarter. Management expects its existing contract-manufacturing arrangements to remain relatively balanced between the third and fourth quarters, while its agreement with Philip Morris International begins contributing in 2027. The company did not provide a financial outlook for that program beyond 2026.
What Investors Should Watch
1. Marlboro’s ability to defend premium economics
Marlboro’s total-category share declined, even as its premium-segment share improved. Investors should watch whether Cowboy Cut can retain value-conscious premium consumers without creating sustained pressure on Marlboro pricing and mix.
2. Discount mix and cigarette margins
Basic is helping Altria preserve overall cigarette share, but the discount category’s continued expansion is a risk to mix. Smokeable margins have remained resilient so far, making price realization and promotional spending important indicators of whether profit growth can continue.
3. On! share within nicotine pouches
On! shipment growth is positive, but the decline in nicotine pouch share is the more consequential measure. A stabilization or recovery in share after the 12-milligram and flavor launches would support Altria’s smoke-free strategy; continued losses would raise questions about the return on higher brand and trade spending.
4. Oral tobacco profit pressure
The oral tobacco segment’s adjusted OCI margin fell 2.8 percentage points in the quarter. Investors should monitor whether pouch growth can become large enough and profitable enough to offset secular declines in Copenhagen and Skoal.
5. NJOY’s market re-entry and regulation
NJOY ACE remains excluded from 2026 guidance. A future re-entry could restore Altria’s e-vapor presence, but management has signaled it will prioritize a disciplined path to profitability in a market still dominated by illicit products. Regulatory enforcement and the FDA’s planned review of its authorization framework will shape that opportunity.
AlgovestIQ Takeaway
Altria delivered a solid quarter on the metrics most important to its near-term financial model. Revenue growth was modest, but cigarette pricing, resilient smokeable margins, ABI earnings and repurchases supported 4.8% adjusted EPS growth and a higher full-year outlook.
The combustible business remains more durable than the headline volume declines suggest. Altria’s cigarette volumes outperformed the broader industry on management’s estimates, and its total retail share increased. The company’s ability to use Basic and Cowboy Cut to retain consumers across price points has helped protect the earnings base during a period of consumer trade-down.
However, the portfolio solution does not eliminate the fundamental risk from an expanding discount segment. Marlboro’s overall category share declined, Marlboro shipment volume fell 6.4%, and more volume is migrating to lower-priced products. Altria must continue to demonstrate that price realization and cost management can offset this mix pressure.
The larger unresolved issue is the smoke-free business. Nicotine pouches are growing quickly, but on!’s pouch-category share is moving in the wrong direction and oral tobacco profits are declining. New strengths, flavors and retail placement could improve competitive performance, but investors will need evidence in retail-share trends and segment margins rather than shipment growth alone.
For now, Altria’s core cash generation continues to support dividends, buybacks and investment. The next test is whether the company can convert those investments into a credible second earnings engine before its legacy tobacco economics face more meaningful deterioration.
How did MO stock react?
MO closed at $76.75 on Oct 29, 2026, up 5.2% from $72.99 on Oct 28, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Oct 28, 2026 (before release) | $72.99 | — |
| Oct 29, 2026 | $76.75 | +5.2% |
| Oct 30, 2026 | $78.03 | +6.9% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- PMPhilip Morris International Q3 2026 Earnings: International Strength Offsets a Heavy U.S. Investment CycleOct 21, 2026
- MDLZMondelēz Q3 2026 Earnings: Volume Growth Returns as Lower Input Costs Lift MarginsOct 29, 2026
- HSYHershey Q3 2026 Earnings: Margin Recovery Offsets Weak Organic VolumeOct 29, 2026
- CLColgate-Palmolive Q3 2026 Earnings: Margin Resilience Offsets a Weak North American QuarterOct 30, 2026
- KOCoca-Cola Q3 2026 Earnings: Volume Growth and Margin Expansion Drive Higher GuidanceOct 27, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Altria Group Q3 FY2026 earnings call transcript, as of Oct 29, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Altria Group Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 29, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 29, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against Altria's earnings release and call transcript before publication. Not investment advice.